India's anti-obesity market, fueled by lower BMI thresholds and Prime Minister Modi's campaign, is growing rapidly, with GLP-1 drugs gaining traction and generics set to slash prices by 2026.

India’s anti-obesity market, valued at over ₹1,000 crore by late 2025, is surging with a 46% CAGR, driven by revised guidelines lowering the obesity BMI threshold to 25 and a national campaign led by Prime Minister Modi to cut edible oil consumption. GLP-1 drugs like Mounjaro, Wegovy, and Ozempic are gaining rapid adoption, with Mounjaro leading in sales despite later entry. As the semaglutide patent expires in March 2026, more than 20 Indian generic manufacturers, including Cipla, Dr Reddy’s, and Sun Pharma, are preparing to launch versions priced 50% to 85% lower, significantly improving access. The market is expected to exceed $1 billion within two years, with pharmaceutical firms expanding reach through digital platforms and partnerships.